Antiepileptic Drugs.

ANTIEPILEPTIC DRUGS -- CONTENTS -- CONTRIBUTING AUTHORS -- PREFACE -- SECTION I GENERAL PRINCIPLES -- 1 PRINCIPLES OF ANTIEPILEPTIC DRUG ACTION -- 2 NEUROPHYSIOLOGIC EFFECTS OF ANTIEPILEPTIC DRUGS -- 3 DISCOVERY AND PRECLINICAL DEVELOPMENT OF ANTIEPILEPTIC DRUGS -- 4 NEW ANTIEPILEPTIC DRUG DEVELOPMENT: MEDICAL PERSPECTIVE -- 5 CLINICAL DEVELOPMENT OF ANTIEPILEPTIC DRUGS: INDUSTRY PERSPECTIVE -- 6 THE DEVELOPMENT OF ANTIEPILEPTIC DRUGS: REGULATORY PERSPECTIVE -- 7 ANTIEPILEPTIC DRUG MONOTHERAPY IN ADULTS: SELECTION AND USE IN NEW-ONSET EPILEPSY -- 8 COMBINATION THERAPY AND DRUG INTERACTIONS -- 9 LABORATORY MONITORING OF ANTIEPILEPTIC DRUGS -- 10 SAFETY MONITORING OF ANTIEPILEPTIC DRUGS -- 11 USE OF ANTIEPILEPTIC DRUGS IN CHILDREN -- 12 ANTIEPILEPTIC DRUG USE IN WOMEN -- 13 EPILEPSY IN THE ELDERLY -- 14 TREATMENT OF STATUS EPILEPTICUS -- 15 PREVENTION OF EPILEPTOGENESIS -- SECTION II BENZODIAZEPINES -- 16 MECHANISMS OF ACTION -- 17 CHEMISTRY, BIOTRANSFORMATION, AND PHARMACOKINETICS -- 18 CLINICAL EFFICACY AND USE IN EPILEPSY -- 19 ADVERSE EFFECTS -- SECTION III CARBAMAZEPINE -- 20 MECHANISMS OF ACTION -- 21 CHEMISTRY, BIOTRANSFORMATION, AND PHARMACOKINETICS -- 22 INTERACTIONS WITH OTHER DRUGS -- 23 CLINICAL EFFICACY AND USE IN EPILEPSY -- 24 CLINICAL EFFICACY AND USE IN OTHER NEUROLOGIC DISORDERS -- 25 CLINICAL EFFICACY AND USE IN PSYCHIATRIC DISORDERS -- 26 ADVERSE EFFECTS -- SECTION IV FELBAMATE -- 27 FELBAMATE -- SECTION V GABAPENTIN -- 28 MECHANISMS OF ACTION -- 29 CHEMISTRY, BIOTRANSFORMATION, PHARMACOKINETICS, AND INTERACTIONS -- 30 CLINICAL USE -- 31 CLINICAL EFFICACY AND USE IN OTHER NEUROLOGICAL DISORDERS -- 32 CLINICAL EFFICACY AND USE IN PSYCHIATRIC DISORDERS -- 33 ADVERSE EFFECTS -- SECTION VI LAMOTRIGINE -- 34 MECHANISMS OF ACTION -- 35 CHEMISTRY, BIOTRANSFORMATION, AND PHARMACOKINETICS -- 36 INTERACTION WITH OTHER DRUGS.

37 CLINICAL EFFICACY AND USE IN EPILEPSY -- 38 EFFICACY AND USE IN PSYCHIATRIC DISORDERS -- 39 ADVERSE EFFECTS -- SECTION VII I LEVETIRACETAM -- 40 MECHANISMS OF ACTION -- 41 CHEMISTRY, BIOTRANSFORMATION, PHARMACOKINETICS, AND DRUG INTERACTIONS -- 42 CLINICAL USE -- 43 ADVERSE EXPERIENCES -- SECTION VIII OXCARBAZEPINE -- 44 MECHANISMS OF ACTION -- 45 CHEMISTRY, BIOTRANSFORMATION, AND PHARMACOKINETICS -- 46 INTERACTIONS WITH OTHER DRUGS -- 47 CLINICAL EFFICACY AND USE IN EPILEPSY -- 48 CLINICAL EFFICACY AND USE IN PSYCHIATRIC DISORDERS -- 49 ADVERSE EFFECTS -- SECTION IX PHENOBARBITAL AND OTHER BARBITURATES -- 50 MECHANISMS OF ACTION -- 51 CHEMISTRY, BIOTRANSFORMATION, AND PHARMACOKINETICS -- 52 INTERACTIONS WITH OTHER DRUGS -- 53 CLINICAL EFFICACY AND USE IN EPILEPSY -- 54 CLINICAL EFFICACY AND USE IN NONEPILEPTIC DISORDERS -- 55 ADVERSE EFFECTS -- 56 METHYLPHENOBARBITAL -- SECTION X PHENYTOIN AND OTHER HYDANTOINS -- 57 MECHANISMS OF ACTION -- 58 CHEMISTRY AND BIOTRANSFORMATION -- 59 INTERACTIONS WITH OTHER DRUGS -- 60 CLINICAL EFFICACY AND USE IN EPILEPSY -- 61 CLINICAL EFFICACY AND USE IN OTHER NEUROLOGICAL DISORDERS -- 62 CLINICAL EFFICACY AND USE IN PSYCHIATRIC DISORDERS -- 63 ADVERSE EFFECTS -- 64 FOSPHENYTOIN -- SECTION XI PRIMIDONE -- 65 PRIMIDONE -- SECTION XII SUCCINIMIDES -- 66 MECHANISMS OF ACTION -- 67 ETHOSUXIMIDE: CHEMISTRY, BIOTRANSFORMATION, PHARMACOKINETICS, AND DRUG INTERACTIONS -- 68 CLINICAL EFFICACY AND USE IN EPILEPSY -- 69 ADVERSE EFFECTS -- 70 METHSUXIMIDE -- SECTION XIII TIAGABINE -- 71 MECHANISMS OF ACTION -- 72 CHEMISTRY, BIOTRANSFORMATION, AND PHARMACOKINETICS -- 73 DRUG INTERACTIONS -- 74 CLINICAL EFFICACY AND USE IN EPILEPSY -- 75 CLINICAL EFFICACY AND USE IN NONEPILEPTIC DISORDERS -- 76 ADVERSE EFFECTS -- SECTION XIV TOPIRAMATE -- 77 MECHANISMS OF ACTION -- 78 CHEMISTRY, BIOTRANSFORMATION, AND PHARMACOKINETICS.

79 DRUG INTERACTIONS -- 80 CLINICAL EFFICACY AND USE IN EPILEPSY -- 81 CLINICAL EFFICACY AND USE IN NONEPILEPTIC DISORDERS -- 82 ADVERSE EFFECTS -- SECTION XV VALPROIC ACID -- 83 MECHANISMS OF ACTION -- 84 CHEMISTRY, BIOTRANSFORMATION, AND PHARMACOKINETICS -- 85 DRUG INTERACTIONS -- 86 CLINICAL EFFICACY AND USE IN EPILEPSY -- 87 CLINICAL EFFICACY AND USE IN OTHER NEUROLOGICAL DISORDERS -- 88 CLINICAL EFFICACY AND USE IN PSYCHIATRIC DISORDERS -- 89 ADVERSE EFFECTS -- SECTION XVI VIGABATRIN -- 90 VIGABATRIN -- SECTION XVII ZONISAMIDE -- 91 MECHANISMS OF ACTION -- 92 CHEMISTRY, BIOTRANSFORMATION, AND PHARMACOKINETICS -- 93 DRUG INTERACTIONS -- 94 CLINICAL EFFICACY AND USE IN EPILEPSY -- 95 ADVERSE EFFECTS -- SECTION XVIII DRUGS IN DEVELOPMENT -- 96 PREGABALIN -- 97 RUFINAMIDE -- 98 DRUGS IN EARLY CLINICAL DEVELOPMENT -- SUBJECT INDEX.

The thoroughly revised, updated Fifth Edition of this classic is the most comprehensive, current, and authoritative reference on all anticonvulsants available today. This edition features detailed profiles of newer drugs--including levetiracetam, oxcarbazepine, tiagabine, topiramate, and zonisamide--and new chapters on use of antiepileptic drugs in children and during pregnancy. Drugs are covered in alphabetical order and in an easy-to-follow format: mechanisms of action; chemistry, biotransformation, and pharmacokinetics; interactions; clinical efficacy and use; and adverse effects. Coverage of clinical use includes nonepileptic and psychiatric disorders where appropriate. This edition has been trimmed to manageable size by shortening chapters on older, less frequently used drugs.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.